NDC-1308

A NOVEL THERAPEUTIC FOR ARDS

INCLUDING COVID-19

“ENDECE is dedicated to the discovery and development of treatments that stop disease progression, restore function, and improve quality of life.”

Dr. James Yarger, Ph.D.

President

LATEST NEWS

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition resulting in a reduction of oxygen that reaches the blood stream and vital organs. Few effective therapeutic modalities exist to treat ARDS, leading to a high mortality rate.

ARDS has many risk factors triggering an inflammatory response culminating in pulmonary injury. Some risk factors for Acute Respiratory Distress Syndrome (ARDS) include advanced age, female gender, smoking, alcohol use, aortic vascular surgery, cardiovascular surgery, traumatic brain injury, and COVID-19.

NDC-1308 A NOVEL THERAPEUTIC FOR ARDS INCLUDING COVID-19

ANTI-INFLAMMATORY

ENDECE developed NDC-1308, a potential treatment for SARS-CoV-2, which has caused the current COVID-19 pandemic. NDC-1308 has the potential to reduce lung inflammation.

ANTIVIRAL

NDC-1308 may have the ability to reduce the number of ACE2 receptors 3 fold in the pulmonary system, reducing viral load in SARS-CoV-2 / COVID-19 patients.